340 related articles for article (PubMed ID: 26594798)
1. Decreased expression of PBLD correlates with poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma.
Li A; Yan Q; Zhao X; Zhong J; Yang H; Feng Z; Du Y; Wang Y; Wang Z; Wang H; Zhou Y; Liu S; Nie Y
Oncotarget; 2016 Jan; 7(1):524-37. PubMed ID: 26594798
[TBL] [Abstract][Full Text] [Related]
2. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
3. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
4. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
6. LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma.
Wang CH; Li M; Liu LL; Zhou RY; Fu J; Zhang CZ; Yun JP
Oncotarget; 2015 Dec; 6(39):42118-29. PubMed ID: 26517349
[TBL] [Abstract][Full Text] [Related]
7. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
8. miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators.
Wang P; Chen S; Fang H; Wu X; Chen D; Peng L; Gao Z; Xie C
Oncotarget; 2016 Jan; 7(1):929-45. PubMed ID: 26498144
[TBL] [Abstract][Full Text] [Related]
9. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
10. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.
Zhao JJ; Pan K; Li JJ; Chen YB; Chen JG; Lv L; Wang DD; Pan QZ; Chen MS; Xia JC
PLoS One; 2011; 6(10):e26608. PubMed ID: 22028922
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting α-SMA.
Pan Y; Qin T; Yin S; Zhang X; Gao X; Mu L
Biomed Pharmacother; 2017 Mar; 87():669-677. PubMed ID: 28088733
[TBL] [Abstract][Full Text] [Related]
12. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY
Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501
[TBL] [Abstract][Full Text] [Related]
13. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma.
Liang B; Chen R; Wang T; Cao L; Liu Y; Yin F; Zhu M; Fan X; Liang Y; Zhang L; Guo Y; Zhao J
Clin Cancer Res; 2013 Jun; 19(11):2905-16. PubMed ID: 23549880
[TBL] [Abstract][Full Text] [Related]
14. Tg737 acts as a key driver of invasion and migration in liver cancer stem cells and correlates with poor prognosis in patients with hepatocellular carcinoma.
You N; Tan Y; Zhou L; Huang X; Wang W; Wang L; Wu K; Mi N; Li J; Zheng L
Exp Cell Res; 2017 Sep; 358(2):217-226. PubMed ID: 28663060
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA AFAP1-AS1 indicates a poor prognosis of hepatocellular carcinoma and promotes cell proliferation and invasion via upregulation of the RhoA/Rac2 signaling.
Zhang JY; Weng MZ; Song FB; Xu YG; Liu Q; Wu JY; Qin J; Jin T; Xu JM
Int J Oncol; 2016 Apr; 48(4):1590-8. PubMed ID: 26892468
[TBL] [Abstract][Full Text] [Related]
16. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
17. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
20. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma.
Cheng J; Xie HY; Xu X; Wu J; Wei X; Su R; Zhang W; Lv Z; Zheng S; Zhou L
Cancer Lett; 2011 Nov; 310(1):35-45. PubMed ID: 21763068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
